In a week full of good news for Esperion Therapeutics (ESPR - Free Report) , shares of the company closed the day up 10% to $48.28 per share.
On Monday, ESPR received approval from the FDA to begin a phase III bridging study of an ongoing study on bempedoic acid. Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol, or LDL-C.
Esperion is currently evaluating bempedoic acid as monotherapy in an ongoing phase III study for a LDL-C lowering indication. The FDA approved a bridging study to be conducted alongside that one to support the approval of a once-daily, oral combination pill that has both bempedoic acid and ezetimibe.
These two therapies strengthen Esperion’s product offerings as both are convenient and cost-effective therapies that can be administered orally. The combination pill could also potentially reach far more patients than the bempedoic acid one alone, creating an opportunity for growth and profit.
Additionally, Stifel Nicolaus restated Esperion stock as a “buy” rating on Monday. Then, on Tuesday, Stifel Financial Corporation (SF - Free Report) acquired 16,883 shares of the company’s stock, investing approximately $601,000. This investment is the latest of financial corporations buying shares of the pharmaceutical company.
And on Tuesday, ESPR traded an unusually high volume of stock, as 1.63 million shares traded hands in 10,832 trades. Over the last month, the company averaged a daily volume of 639,366 shares.
In general, a company benefits when its stock experiences a sudden spike in trading volume. An increase in volume traded means there is greater awareness of the company, which could potentially help the stock rise in price. The rise in volume also creates support and stability for price advances.
ESPR remains a Zacks Rank #3 (Hold). The pharmaceutical company has its work cut out for it, but it has positive growth estimates in the year ahead.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
In a week full of good news for Esperion Therapeutics (ESPR - Free Report) , shares of the company closed the day up 10% to $48.28 per share.
On Monday, ESPR received approval from the FDA to begin a phase III bridging study of an ongoing study on bempedoic acid. Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol, or LDL-C.
Esperion is currently evaluating bempedoic acid as monotherapy in an ongoing phase III study for a LDL-C lowering indication. The FDA approved a bridging study to be conducted alongside that one to support the approval of a once-daily, oral combination pill that has both bempedoic acid and ezetimibe.
These two therapies strengthen Esperion’s product offerings as both are convenient and cost-effective therapies that can be administered orally. The combination pill could also potentially reach far more patients than the bempedoic acid one alone, creating an opportunity for growth and profit.
Additionally, Stifel Nicolaus restated Esperion stock as a “buy” rating on Monday. Then, on Tuesday, Stifel Financial Corporation (SF - Free Report) acquired 16,883 shares of the company’s stock, investing approximately $601,000. This investment is the latest of financial corporations buying shares of the pharmaceutical company.
And on Tuesday, ESPR traded an unusually high volume of stock, as 1.63 million shares traded hands in 10,832 trades. Over the last month, the company averaged a daily volume of 639,366 shares.
In general, a company benefits when its stock experiences a sudden spike in trading volume. An increase in volume traded means there is greater awareness of the company, which could potentially help the stock rise in price. The rise in volume also creates support and stability for price advances.
ESPR remains a Zacks Rank #3 (Hold). The pharmaceutical company has its work cut out for it, but it has positive growth estimates in the year ahead.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on SF - FREE
Get the latest research report on ESPR - FREE